RxDoctor Payments Data

Shamsideen Musa, MD

Anesthesiology · Anchorage, AKNPI 1649616459

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (58.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Medtronic at 52.5% of the total. Reporting peaked in 2022 at $10,195 and has fallen 68.6% since, to $3,206 in 2025. Among anesthesiology clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,475in general payments, 2019–2025

Across 350 payments — averaging $104.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Abbott$4K
  • Boston Scientific$3K
  • Globus Medical$2K
  • Vertos Medical, Inc.$1K
  • Genesys Orthopedics Systems, L.L.C.$1K
  • plus $5K from 29 others

What the payments were for

  • Speaking & faculty fees$6752%
  • Travel & lodging$21,30758%
  • Food & beverage$14,41940%
  • Education$630%
  • Gifts$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,475 in reported general payments places this provider in the 95th percentile of 101 anesthesiology providers in Alaska.

See all anesthesiology providers in Alaska

Medicare billing

Part B allowed, 2024
$151,383
Medicare patients
101
Services billed
1,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant15$15,343
Xtampza ErOxycodone Myristate13$9,730
Oxycodone Hcl145$3,179
Lidocaine43$2,526
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$2,413
Celecoxib15$1,628
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$1,605
Gabapentin81$1,325
Tramadol Hcl38$1,030
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen40$928
Morphine Sulfate ErMorphine Sulfate37$717
Pregabalin55$716
Diclofenac Sodium25$485
Lidocaine-PrilocaineLidocaine/Prilocaine11$426
Morphine Sulfate13$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$605$15,34315 claims
Collegium Pharmaceutical, Inc.Xtampza Er$24$9,73013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 anesthesiology providers in Alaska.

Other anesthesiology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →